No Data
No Data
Zura Bio's Latest Market Insights Yet to Be Filed
Zura Bio Announces Participation in June Investor Conferences
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will
Express News | Zura Bio Ltd Files for Resale of up to 41.6 Mln Class a Ordinary Shares by the Selling Securityholders - SEC Filing
Zura Bio(ZURA.US) Director Buys US$496K in Common Stock
$Zura Bio(ZURA.US)$ Director Ploos van Amstel Arnout purchased 80,000 shares of common stock on May 17, 2024 at an average price of $6.2 for a total value of $496K.Source: Announcement What is stateme
10-Q/A: Quarterly report (Amendment)
Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
No Data